Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors
批准号:
7539416
负责人:
Adam Peter Mecca
金额:
$3.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-16 至 2013-08-15
关键词:
Adrenergic ReceptorAngiotensin IIAngiotensin II ReceptorAngiotensin II Type 1 Receptor BlockersAnimal ModelAntihypertensive AgentsBrainCause of DeathCerebrovascular CirculationCerebrumClinical TrialsCorpus striatum structureDataDevelopmentDiseaseEndothelin-1FellowshipGene DeliveryGene TransferGoalsHypotensionInfarctionInstitutesInvestigationIschemic StrokeLifeMediatingMiddle Cerebral Artery OcclusionMissionMolecularNational Research Service AwardsNeuritesNeurologicNeuronsPeptidesPharmaceutical PreparationsPlayPublic HealthRattusReceptor ActivationReceptor GeneReceptor, Angiotensin, Type 1RoleStrokeSymptomsTestingType 2 Angiotensin II ReceptorUnited StatesViralWorkbasedisabilityimprovedin vivonervous system disordernovel therapeuticspre-doctoralpreferencereceptorreceptor expressionrelating to nervous systemresearch studysizesmall hairpin RNAtherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Stroke is the third leading cause of death in the United States and a major cause of serious, long-term disability. Understanding the mechanisms that underlie stroke and the development of new therapeutic strategies is of key importance and is the long-term objective of this study. Much experimental evidence points to a beneficial action of angiotensin II type 2 receptors (AT2R) in stroke that is enhanced in the presence of Ang II type 1 receptor (AT1R) blockers (ARBs), drugs that are effective anti-stroke agents. Thus, we have developed the general hypothesis that neuronal over expression of AT2R in the cerebral cortical and striatal regions will provide protection during ischemic stroke. In addition, we hypothesize that the combination of AT2R over expression and ARB administration will provide additional cerebroprotection than either alone. Specifically, we hypothesize that viral-mediated delivery of the AT2R gene and consequent neuronal over expression of AT2R within the cortical and striatal regions will reduce the infarct size and neurological deficits resulting from experimentally induced stroke. We further hypothesize that viral mediated delivery of an AT2R shRNA and consequent reduction in AT2R expression will exacerbate the neurological deficits and increase infarct size. The goal of this proposal is to test these hypotheses, using a combination of gene transfer, molecular, cellular and in vivo experimental approaches. The data from this study will not only help to solidify a cerebroprotective role of AT2R in stroke, but will help to determine whether the over expression of AT2R in the CMS can elicit a beneficial action. The specific aims are: (1) Characterize viral-mediated over expression and reduction of AT2R in rat cerebral cortical and striatal regions. (2)Determine whether viral-mediated neuronal over expression of AT2R elicits cerebroprotection during ischemic stroke and improves the cerebroprotective action of ARBs. (3)Determine whether viralmediated reduction of neuronal AT2R potentiates the neural damage elicited by ischemic stroke and reduces the cerebroprotective action of ARBs. In summary, the experiments proposed here will not only allow us to solidify a cerebroprotective role of AT2R in stroke, but will also allow us to determine whether over expression of AT2R in the CNS can provide a beneficial action alone or in in combination with ARBs.
PUBLIC HEALTH RELEVANCE: These studies are relevant to public health as they will help to understand what happens in the brain after a stroke occurs, and may identify a new therapeutic target that would be helpful in reducing stroke symptoms. This is clearly relevant to the mission of the National Institutes of Neurological Disorders and Stroke.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease
-
批准号:10491751
-
项目类别:
-
资助金额:$154.37万
-
财政年份:2021
-
负责人:Adam Peter Mecca
-
依托单位:
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease
-
批准号:10274526
-
项目类别:
-
资助金额:$196.79万
-
财政年份:2021
-
负责人:Adam Peter Mecca
-
依托单位:
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.
-
批准号:10343716
-
项目类别:
-
资助金额:$19.54万
-
财政年份:2018
-
负责人:Adam Peter Mecca
-
依托单位:
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.
-
批准号:10063934
-
项目类别:
-
资助金额:$19.54万
-
财政年份:2018
-
负责人:Adam Peter Mecca
-
依托单位:
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors
-
批准号:7662392
-
项目类别:
-
资助金额:$3.12万
-
财政年份:2008
-
负责人:Adam Peter Mecca
-
依托单位:
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors
-
批准号:8115066
-
项目类别:
-
资助金额:$3.96万
-
财政年份:2008
-
负责人:Adam Peter Mecca
-
依托单位:
海外基金